Igene Biotechnology, Inc.
IGNE
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Net Income | -111.76% | 19.79% | 42.79% | 96.47% | 63.19% |
| Total Depreciation and Amortization | -44.94% | -47.66% | -49.84% | -51.26% | 46.86% |
| Total Amortization of Deferred Charges | -95.70% | -98.26% | -98.91% | -99.20% | -82.97% |
| Total Other Non-Cash Items | -243.75% | 113.70% | 45.04% | -31,241.67% | -215.21% |
| Change in Net Operating Assets | -8.57% | -78.69% | 216.27% | -30.71% | -36.13% |
| Cash from Operations | -280.50% | -221.28% | 115.58% | -113.76% | -47.06% |
| Capital Expenditure | 109.70% | 108.18% | 111.47% | 24.05% | 67.48% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 109.94% | 108.38% | 111.47% | 24.05% | 78.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | 35.79% | 466.67% | 125.56% | 527.53% | -68.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -314.47% | -306.70% | 116.12% | -141.76% | -22.61% |